目的探讨bcl-2、bcl-6、CD10、MUM1在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达及与亚分类的关系。方法应用免疫组织化学S-P法,检测60例弥漫性大B细胞淋巴瘤标本中bcl-2、bcl-6、CD10、MUM1蛋白的表达水平。结...目的探讨bcl-2、bcl-6、CD10、MUM1在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达及与亚分类的关系。方法应用免疫组织化学S-P法,检测60例弥漫性大B细胞淋巴瘤标本中bcl-2、bcl-6、CD10、MUM1蛋白的表达水平。结果bcl-2、bcl-6、CD10、MUM1在60例弥漫性大B细胞淋巴瘤中的表达率分别为55.0%(33/60)、48.3%(29/60)、46.7%(28/60)、58.3%(35/60),其中GCB占55.0%(33/60),non-GCB占45.0%(27/60)。GCB、non-GCB中bcl-2的表达差异具有显著性。在non-GCB中,bcl-6+与bcl-6-的病例bcl-2表达的差异具有显著性。结论该组病例GCB所占的比率超过non-GCB,bcl-2在DLBCL亚分类中可能具有一定的作用。展开更多
弥漫大B细胞淋巴瘤（diffused large B cell lym-plaoma,DLBCL）是非霍奇金淋巴瘤（NHL）中最大的一个亚群,是成人最常见的NHL[1],约占NHL总数的30%～40%[2].在WHO关于淋巴系统肿瘤的分类[3]中,DLBCL被定义为：B细胞起源的,有大的肿瘤细...弥漫大B细胞淋巴瘤（diffused large B cell lym-plaoma,DLBCL）是非霍奇金淋巴瘤（NHL）中最大的一个亚群,是成人最常见的NHL[1],约占NHL总数的30%～40%[2].在WHO关于淋巴系统肿瘤的分类[3]中,DLBCL被定义为：B细胞起源的,有大的肿瘤细胞,具有侵袭性临床表现,需要高效力化疗的一组恶性淋巴瘤,这类肿瘤发生于淋巴结内或结外,可原发或继发于其他低度恶性淋巴瘤的演进[4].展开更多
Background: Systemic B-cell lymphomas have been studied using microarrays, which has led to a better understanding of their molecular characteristics. Initial microarray studies of these lymphomas have implicated seve...Background: Systemic B-cell lymphomas have been studied using microarrays, which has led to a better understanding of their molecular characteristics. Initial microarray studies of these lymphomas have implicated several genes as important predictors of outcome. In this study, we used a tissue micro-array (TMA) to characterize primary cutaneous large B-cell lymphomas (PCLBCL). Methods: We studied 14 patients for whom clinical follow up was available, including four patients whose lesions were limited to the leg on presentation. Immunohistochemical staining with CD20, CD44, CD21, CD5, CD10, bcl-2, bcl-6, Ki67, p53, and multiple myeloma 1 (MUM1) was examined. Results: Our results identify two subgroups of lymphomas. The first group showed staining with bcl-6 and had an overall survival of 176 months (P=0.003). The majority of this group was negative for MUM1. The second group lacked staining with bcl-6 and had an overall survival of 26 months, with a majority of these cases staining with MUM1. Three of four patients with PCLBCL of the leg showed no staining with bcl-6. Conclusions: Our study demonstrates the utility of TMAs in the analysis of PCLBCL and that expression of bcl-6 and MUM1 correlates with survival.展开更多
文摘目的探讨bcl-2、bcl-6、CD10、MUM1在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达及与亚分类的关系。方法应用免疫组织化学S-P法,检测60例弥漫性大B细胞淋巴瘤标本中bcl-2、bcl-6、CD10、MUM1蛋白的表达水平。结果bcl-2、bcl-6、CD10、MUM1在60例弥漫性大B细胞淋巴瘤中的表达率分别为55.0%(33/60)、48.3%(29/60)、46.7%(28/60)、58.3%(35/60),其中GCB占55.0%(33/60),non-GCB占45.0%(27/60)。GCB、non-GCB中bcl-2的表达差异具有显著性。在non-GCB中,bcl-6+与bcl-6-的病例bcl-2表达的差异具有显著性。结论该组病例GCB所占的比率超过non-GCB,bcl-2在DLBCL亚分类中可能具有一定的作用。
文摘弥漫大B细胞淋巴瘤（diffused large B cell lym-plaoma,DLBCL）是非霍奇金淋巴瘤（NHL）中最大的一个亚群,是成人最常见的NHL[1],约占NHL总数的30%～40%[2].在WHO关于淋巴系统肿瘤的分类[3]中,DLBCL被定义为：B细胞起源的,有大的肿瘤细胞,具有侵袭性临床表现,需要高效力化疗的一组恶性淋巴瘤,这类肿瘤发生于淋巴结内或结外,可原发或继发于其他低度恶性淋巴瘤的演进[4].
文摘Background: Systemic B-cell lymphomas have been studied using microarrays, which has led to a better understanding of their molecular characteristics. Initial microarray studies of these lymphomas have implicated several genes as important predictors of outcome. In this study, we used a tissue micro-array (TMA) to characterize primary cutaneous large B-cell lymphomas (PCLBCL). Methods: We studied 14 patients for whom clinical follow up was available, including four patients whose lesions were limited to the leg on presentation. Immunohistochemical staining with CD20, CD44, CD21, CD5, CD10, bcl-2, bcl-6, Ki67, p53, and multiple myeloma 1 (MUM1) was examined. Results: Our results identify two subgroups of lymphomas. The first group showed staining with bcl-6 and had an overall survival of 176 months (P=0.003). The majority of this group was negative for MUM1. The second group lacked staining with bcl-6 and had an overall survival of 26 months, with a majority of these cases staining with MUM1. Three of four patients with PCLBCL of the leg showed no staining with bcl-6. Conclusions: Our study demonstrates the utility of TMAs in the analysis of PCLBCL and that expression of bcl-6 and MUM1 correlates with survival.
